Stanford University School of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2015

  1. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

    Circulation, Vol. 132, Núm. 1, pp. 27-39

  2. The effects of cinacalcet in older and younger patients on hemodialysis: The evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial

    Clinical Journal of the American Society of Nephrology, Vol. 10, Núm. 5, pp. 791-799